EFFECTIVENESS OF LISINOPRIL AND AMLODIPINE COMBINATION AT HYPERTENSION WITH COMORBIDITY OF ARTERIOSCLEROSIS OBLITERANS IN GENERAL PRACTICE.

OBJECTIVE: The aim: To analyze the dynamics of daily monitoring of blood pressure, intracardiac (according to echocardiography), peripheral hemodynamics (according to ultrasound of the vessels of the lower extremity), the thickness of the intima-media complex (according to carotid sonography) in patients with hypertension the effect of treatment with a combination of lisinopril and amlodipine. PATIENTS AND METHODS: Materials and methods: The study included 40 patients with hypertension with 2 (29 patients) and 3 (11 patients) degrees of hypertension in combination with AOLE with I-III stages of chronic insufficiency of the lower extremity, which revealed hyperkinetic, eukinetic, and hypokinetic types of hypertension with a predominance of the sympathetic nervous system. The groups are comparable in age, sex, duration of hypertension, and medications received in the previous stages. For antihypertensive therapy, the most common drugs for use were selected - lisinopril + amplodipine in fixed doses of 10 and 5 mg, respectively. If after 2 weeks we did not reduce the mean level of SBP and DBP by 10% or more from baseline, we doubled the dose of lisinopril without changing the dose of amlodipine. RESULTS: Results: After 6 months of treatment, in particular, an increase in the pulse index - by 24.8%, a decrease in the resistance index - by 21.1%, an increase in linear and volumetric blood velocity - by 25.6% and 27.4%, respectively, while achieving the target blood pressure. CONCLUSION: Conclusions: It is proved that in the absence of individual contraindications the combination of lisinopril and amlodipine is optimal and universal for effective treatment of patients with hypertension in combination with AOLE in all types of central hemodynamics.

METABOLIC THERAPY IN THE COMPLEX TREATMENT OF CHRONIC PANCREATITIS WITH STABLE CORONARY ARTERY DISEASE.

OBJECTIVE: The aim: To study the effectiveness of using medicine meldonium in standard therapy to the correction of prooxidant-antioxidant and kallikrein-kinin disorders in patients with chronic pancreatitis andstable coronary artery disease. PATIENTS AND METHODS: Materials and methods: The study included 90 patients with chronic pancreatitis andstable coronary artery disease.They were divided into two groups: I group (45 patients) received standard treatment; II group (45 patients) along with basic therapy received medication meldonium (Vazonat) for 2 capsules (500 mg) once daily for two months. Indicators prooxidant-antioxidant system in blood plasma was determined by biochemical method, indicators of kallikrein-kinin system- by chromatographic method. RESULTS: Results: The better status of the prooxidant-antioxidant system and kallikrein-kinin system was observed in patients who received in addition to standard protocol treatment with meldonium. CONCLUSION: Conclusions: Adding to the complex therapy of patients with chronic pancreatitis and stable coronary artery disease of the medicine meldonium helps to improve the prooxidation-antioxidant status and disorders in the kallikrein-kinin system more significantly compared with standard basic therapy.